Drug Information

Drug General Information
Drug ID
D00EQY
Former ID
DIB008094
Drug Name
KTN3379
Drug Type
Antibody
Indication Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10:C00-C75, C7A, C7B, D10-D36, D3A] Phase 1 [524573]
Company
Kolltan pharmaceuticals
Target and Pathway
Target(s) Receptor protein-tyrosine kinase erbB-3 Target Info [544480]
KEGG Pathway ErbB signaling pathway
Calcium signaling pathway
Endocytosis
Proteoglycans in cancer
MicroRNAs in cancer
NetPath Pathway TNFalpha Signaling Pathway
PANTHER Pathway Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database ErbB2/ErbB3 signaling events
ErbB receptor signaling network
a6b1 and a6b4 Integrin signaling
WikiPathways ErbB Signaling Pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
Signaling Pathways in Glioblastoma
miR-targeted genes in muscle cell - TarBase
Heart Development
References
Ref 524573ClinicalTrials.gov (NCT02014909) A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors. U.S. National Institutes of Health.
Ref 544480A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.